
==== Front
J Clin Invest
J Clin Invest
J Clin Invest
The Journal of Clinical Investigation
0021-9738
1558-8238
American Society for Clinical Investigation

180073
10.1172/JCI180073
Review Series
Metabolic benefits afforded by estradiol and testosterone in both sexes: clinical considerations
https://orcid.org/0000-0002-0874-0754
Mauvais-Jarvis Franck fmauvais@tulane.edu
123
Lindsey Sarah H. lindsey@tulane.edu
34
1 Medicine Service, Section of Endocrinology, Hormone Therapy Clinic, Southeast Louisiana VA Medical Center, New Orleans, Louisiana, USA.
2 Deming Department of Medicine, Section of Endocrinology and Metabolism, Tulane University School of Medicine, New Orleans, Louisiana, USA.
3 Tulane Center of Excellence in Sex-Based Biology & Medicine, New Orleans, Louisiana, USA.
4 Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Address correspondence to: Franck Mauvais-Jarvis, 1340 Tulane Avenue, SL53, New Orleans, Louisiana 70112, USA. Email: fmauvais@tulane.edu.
3 9 2024
3 9 2024
3 9 2024
134 17 e180073© 2024 Mauvais-Jarvis﻿﻿﻿﻿,﻿﻿,﻿ et al.
2024
Mauvais-Jarvis﻿﻿﻿﻿,﻿﻿,﻿ et al.
https://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
This article is available online at https://www.jci.org/articles/view/180073
Testosterone (T) and 17β-estradiol (E2) are produced in male and female humans and are potent metabolic regulators in both sexes. When E2 and T production stops or decreases during aging, metabolic dysfunction develops and promotes degenerative metabolic and vascular disease. Here, we discuss the shared benefits afforded by E2 and T for metabolic function human females and males. In females, E2 is central to bone and vascular health, subcutaneous adipose tissue distribution, skeletal muscle insulin sensitivity, antiinflammatory immune function, and mitochondrial health. However, T also plays a role in female skeletal, vascular, and metabolic health. In males, T’s conversion to E2 is fundamental to bone and vascular health, as well as prevention of excess visceral adiposity and the promotion of insulin sensitivity via activation of the estrogen receptors. However, T and its metabolite dihydrotestosterone also prevent excess visceral adiposity and promote skeletal muscle growth and insulin sensitivity via activation of the androgen receptor. In conclusion, T and E2 are produced in both sexes at sex-specific concentrations and provide similar and potent metabolic benefits. Optimizing levels of both hormones may be beneficial to protect patients from cardiometabolic disease and frailty during aging, which requires further study.
==== Body
pmcIntroduction

Testosterone (T) and 17β-estradiol (E2) are considered male and female sex hormones, respectively, because they are secreted by gonads in the circulation at sex-specific concentrations and are involved in sexual differentiation and reproduction. E2, however, is not exclusively a female hormone since, for example, it is essential for erection and libido in male individuals (1). Likewise, T is not exclusively a male hormone, as it is essential for libido in female individuals (2). Most importantly, E2 and T are central to metabolic homeostasis of most cells and in both sexes. When E2 and T production stops or decreases during aging, metabolic dysfunction develops and promotes degenerative metabolic and vascular disease. Understanding the sex-specific and shared benefits of E2 and T in metabolic function in both sexes is critical to medicine and healthy aging. Here, we analyze sex differences and similarities in E2 and T benefits for metabolic homeostasis in male and female humans, including glucose and lipid metabolism, bone, vascular, adipose, muscle, and immune functions, and the prevention of metabolic dysfunction leading to cardiometabolic disease. We use the terms male and female to describe the biological sex of human subjects through the paper and we specify when animal studies are discussed. For details on mechanisms of E2 and T’s actions, we will refer to recent and landmark reviews.

Origin of T and E2 in both sexes

In males, all T is produced by Leydig cells of the testis. T behaves as a hormone by binding the androgen receptor (AR), and also behaves as a prohormone that is converted in peripheral tissues to E2 or dihydrotestosterone (DHT), a pure AR agonist that cannot be converted to E2. In males, most E2 (80%) is formed via aromatization of circulating T in the periphery. The testes directly produce approximately 20% of circulating E2 (3) (Figure 1A). Circulating concentrations of E2 in males are half of those of females and are essential to metabolic homeostasis, as we will discuss. In females of reproductive age, the granulosa cells of the ovaries produce E2, the major circulating estrogen (Figure 1B). After menopause, estrone (E1) becomes the major circulating estrogen (4). E1 is produced by aromatization from the adrenal androgen androstenedione in adipose tissue (5) (Figure 1C). E1 is a weak estrogen and should be considered a reservoir of the more potent E2 in postmenopausal females. E2 is produced locally in extra-ovarian tissues and acts locally as a paracrine and intracrine factor (Figure 1). In females, T is the most abundant circulating active sex steroid throughout the life span (Figure 2). In females of reproductive age, T is produced by the ovary (25%), the adrenal gland (25%), and in peripheral tissues (50%), following conversion from circulating androstenedione (equally produced by the ovary and the adrenal gland) (6–9) (Figure 1B). After natural menopause, ovarian T production decreases slowly. T is mainly produced by the ovaries (50%) and via peripheral conversion from androstenedione (40%) mainly of adrenal origin (6–9). Direct adrenal production of T is minor (around 10%) (Figure 1C). Although T is ten times less abundant in the blood of females than males, in females across the life span, circulating T is 5–50 times more abundant than E2 (Figure 2), the implications of which we will discuss below.

E2 promotes metabolic homeostasis in females

In females of reproductive age, E2 is instrumental to skeletal, vascular, and energy homeostasis. The central role of E2 in maintenance of bone metabolism, the detrimental effect of postmenopausal E2 deficiency on osteopenia and osteoporosis, and their prevention by estrogen therapy in postmenopausal females is evidence-based medicine (10, 11) and will not be discussed here.

E2 promotes female vascular function and health.

Females with early E2 deficiency because of surgical oophorectomy (12, 13), premature ovarian insufficiency (14), or early menopause (15) are at increased risk of cardiovascular disease (CVD) and mortality compared with females who experience natural menopause. As we will discuss below, the vascular protection provided by E2 extends to males through T conversion. E2 protects arteries by promoting vasodilation, either through stimulation of nitric oxide (NO) production in endothelial cells or direct effects on dilatory mechanisms within vascular smooth muscle. Brachial artery flow–mediated dilation (FMD) is NO mediated (16) and is considered the gold standard for assessing macrovascular endothelial health because it is a strong predictor of future CVD (17). E2 increases FMD at puberty in females (18) and maintains greater FMD in reproductive-aged females versus males (19), while E2 deficiency after menopause reduces FMD (20). This ability of E2 to improve vascular tone is integral for its protection against high blood pressure, supported by the increased incidence of hypertension after surgical or early menopause (21). In rodent models that display male predominance in hypertension, ovariectomy in females increased blood pressure to the level of male rodents (22). The association of menopausal hormone therapy with hypertension is observed only with oral estrogens, especially conjugated equine estrogens (CEEs) and oral estrogen in combination with synthetic progestogens, not progesterone, highlighting the importance of differentiating endogenous versus synthetic hormones as well as route of administration (23, 24).

The second mechanism for the vascular protection provided by E2 relates to its ability to prevent detrimental remodeling, including fibrosis, stiffening, and calcification. Pulse wave velocity is a clinical measure of arterial stiffness and a strong predictor of cardiovascular events (25). Supporting the importance of E2 in protecting from arterial stiffness, females exhibited lower arterial stiffness than males only between puberty and menopause (26). Stiffness significantly increased in females at menopause (27), and in fact females developed higher arterial stiffness than age-matched males despite similar blood pressure (28). Thus, E2 deficiency amplifies arterial stiffness in a female-specific manner.

The third mechanism of E2 vascular protection involves its ability to lower atherogenic lipids (discussed in the corresponding section) and to decrease systemic inflammation. Females display a more robust immune response to infection and vaccination than males, but are more susceptible to autoimmune diseases (29). E2 reduces proinflammatory cytokines through direct immunomodulatory actions on immune cells (30). Atherosclerosis is a chronic inflammatory disease, characterized by elevated lipids and macrophage infiltration into the vascular wall, and mouse models show that E2 is atheroprotective, especially in the early stages of lesion formation (31).

Why the vascular benefits provided by endogenous E2 and demonstrated in females with early E2 deficiency do not always translate to protection by exogenous menopausal estrogen therapy is a subject of ongoing debate. Several hypotheses have been proposed, the first of which is that endogenous E2 prevents or slows the progression of CVD, but does not reverse established vascular damage. If E2 is not restored early, then irreversible damage develops that cannot be reversed. This theory underlies the “timing hypothesis,” which postulates that E2 therapy started at the time of menopause in a woman with healthy arteries prevents the development of CVD, but beyond a certain point, the age- and E2 deficiency–related damage renders the effects of E2 less beneficial and potentially harmful (32). In support of this, a meta-analysis of 19 randomized controlled trials of over 40,000 postmenopausal women concluded that women who initiate estrogen therapy within 10 years of menopause show a 50% reduction in cardiovascular mortality and myocardial infarction (MI) (33). The mechanism for this early protection could be that actions mediated by ERα, but not ERβ, are protective, but prolonged E2 deficiency decreases the vascular ERα/ERβ ratio (34). In addition, the increased CVD observed in older postmenopausal women was related to the use of CEE therapy, not E2 (35). CEE contains mostly E1, a poor ERα agonist, along with several equine estrogens that exhibit greater affinity for ERβ (36) and are inferior to E2 with regard to NO production (37). Thus, CEE is likely to exhibit different vascular actions than E2. In summary, current evidence indicates that endogenous E2 prevents damage in a healthy vascular system following short-term E2 deficiency, but does not protect vessels exposed to prolonged E2 deficiency (Figure 3).

E2 promotes subcutaneous lipid storage in females.

A major evolutionary function of E2 is to facilitate postprandial lipid storage in subcutaneous adipose tissue (SCAT) to prepare for pregnancy (38). Thus, premenopausal females carry more SCAT than males because higher circulating concentrations of E2 in females favors SCAT expansion and inhibits visceral adipose tissue (VAT) development. The best evidence is found in transgender individuals assigned male sex at birth who were treated with high doses of estrogens (in the presence of antiandrogens) as gender-affirming therapy. These individuals accumulated preferential SCAT in the leg and gynoid region, which increased hip circumference (39). After menopause, E2 deficiency leads to VAT accumulation, but it is reduced by estrogen therapy (40). As we will discuss below, T’s conversion to E2 is also instrumental in preventing VAT accumulation in males. In females, endogenous E2 also promoted lipid oxidation in skeletal muscle during fasting and exercise, but inhibited hepatic lipid oxidation during the fed and resting periods, which promoted energy storage in SCAT (38). Estrogens taken orally also increased hepatic de novo lipogenesis and triglyceride synthesis for export into very-low-density lipoproteins (VLDLs) that can be taken up by the expanded SCAT to promote lipid storage (41). After menopause, E2 deficiency decreases lipid oxidation and leads to disinhibition of VAT accumulation. In summary, E2 promotes lipid oxidation in fasting and SCAT expansion to promote lipid storage in fed and resting states while inhibiting VAT development, which produces the female gynoid phenotype.

E2 promotes glucose and lipid homeostasis in females.

E2 is an antidiabetic hormone; thus, deficiency increases the risk of new-onset type 2 diabetes (T2D) (42). In postmenopausal women, estrogen therapy reduces the incidence of new-onset T2D and improved glycemia in women with diabetes. In postmenopausal women with T2D, estrogen therapy reduced fasting glucose and insulin as well as HbA1c (a marker of chronic hyperglycemia), and decreased the homeostatic model assessment for insulin resistance (HOMA-IR) index to a greater extent than in postmenopausal women without diabetes (40, 43). Estrogens administered orally produced a greater decrease in diabetes risk than the transdermal route (44). The stronger effect of oral estrogens on blood glucose results from first-pass liver metabolism, which better suppresses hepatic glucose output (45). The beneficial effects of endogenous E2 can be inferred from studies using animal models suggesting that E2 enhances insulin sensitivity via ERα in liver and skeletal muscle (42, 45) and protects muscle mitochondrial function, which is essential to female insulin sensitivity (46) (see also section below).

Endogenous and exogenous estrogens also protect β cell function and insulin secretion, as shown in preclinical and clinical studies (42, 47–51). This effect is less apparent clinically because the hyperbolic relationship between insulin sensitivity and β cell function (i.e., disposition index) produces a dynamic compensation of the E2-induced improvement in insulin sensitivity by reducing insulin secretion. Endogenous E2 and exogenous estrogens produce beneficial effects on cholesterol and inflammatory markers. Women experience an increase in low-density lipoprotein (LDL) cholesterol during perimenopause (52), and estrogen therapy is protective. In meta-analyses, estrogens reduce the ratio of LDL/high-density lipoprotein (HDL) cholesterol, lipoprotein (a), and the inflammatory markers E-selectin and plasminogen activator inhibitor-1 (40). In summary, E2 is critical in females for maintaining glucose and lipid homeostasis, which is reproduced by estrogen therapy and, as discussed below in “T promotes metabolic homeostasis in males,” is also true in males.

E2 promotes mitochondrial fitness in females.

E2 allows women to transmit the fittest mitochondria to prevent the transmission of inherited disease (38). In female rodents, E2 promotes higher mitochondrial antioxidant enzyme activity, decreases reactive oxygen species production, and reduces damage to mitochondria DNA (mtDNA) compared with male rodents. In addition, E2 via nuclear ERα and ERβ activates a transcriptional cascade culminating in the expression of mitochondrial respiratory chain complexes (53, 54). E2 acting on mitochondrial ERα or ERβ also maintains mitochondrial dynamics and promotes mitochondrial fusion while attenuating fission (46, 55). In summary, E2 promotes female mitochondrial quality with higher respiratory capacities, biogenesis, and resistance to oxidative stress (56). Figure 3 summarizes the effects of E2 on female metabolic homeostasis.

The importance of T in female metabolic homeostasis

T production favors healthy body composition in females.

Supraphysiological levels of T in women such as those achieved during polycystic ovarian syndrome are associated with insulin resistance, visceral obesity, and T2D, demonstrating the metabolic impact of T in females (57). However, although clinical trials have focused of the effects of T supplementation in postmenopausal women with regard to libido and well being, the physiological impact of T in female metabolic homeostasis has not been explored. This lack of knowledge is surprising since, as discussed above, in females, T is always more abundant than E2 (Figure 2). In addition, studies have documented wide AR expression across female human tissues (58) and strong AR genomic localization in female rat tissues despite low levels of AR protein compared with male rats (59). An example that illustrates the physiological role of T in female metabolism is its conversion to active steroids in pancreatic islet β cells. Female mouse and human β cells are equipped with the enzymes aromatase and 5α-reductase (5α-R) to convert circulating T to E2 and DHT, respectively (60). Intracrine conversion of T to E2 or DHT by these enzymes was observed in female human islets, and this enhanced insulin secretion (60). In androgen-deficient women (as a result of hypopituitarism, oophorectomy, or natural menopause), T treatment that produced concentrations in the female physiological range increased lean mass (bone density and muscle mass) and decreased fat mass (61–67), improved insulin resistance (62, 68), and decreased inflammation (69, 70). T even improved aerobic capacity, muscle performance, and effort tolerance in postmenopausal females with advanced chronic heart failure (62). It is unknown to what extent the effect of T on fat mass and insulin sensitivity in females is mediated via aromatization to E2. However, the effect on muscle mass is likely mediated via T or DHT acting on AR, as discussed for males below. In addition, in postmenopausal females, T enhanced the effect of E2 in increasing bone mineral density, suggesting that T acting on AR is also important for maintenance of female bone strength (66, 67). Indeed, female mice lacking AR display reduced trabecular bone mass (71).

Physiological T production protects female vascular health.

Hyperandrogenism in women of reproductive age has been associated with subclinical markers of atherosclerotic CVD, such as arterial stiffness, carotid intima media thickness, coronary artery calcification, endothelial dysfunction, and CVD (72). The administration of high-dose T was also associated with atherosclerosis in postmenopausal women (73). In contrast, low endogenous T in women has been prospectively associated with increased all-cause mortality and incident CVD independent of other risk factors (74). Thus, a physiological window of T seems necessary for female vascular health. Indeed, throughout the female life span, higher T concentrations within the physiological range have been associated with lower carotid intimal-medial thickness (75). Conversely, lower T concentrations were associated with carotid atherosclerosis (76, 77) and coronary artery disease (CAD) (78) in females. The mechanisms by which T promotes vascular health in females may involve a reduction in CV risk factors; apolipoprotein CIII (apoCIII) impairs the metabolism of VLDL and LDL, increasing triglycerides, and thus is a strong predictor of CAD (79). In women with surgical menopause, T added to estrogens reduced the apoCIII concentration selectively in VLDL and LDL compared with estrogens alone, which was expected to improve CAD risk (70). Addition of T to oral E2 counteracts the E2-induced rise in the inflammatory marker C-reactive protein (CRP) in postmenopausal females (69). T also promoted arterial vasodilation in postmenopausal females who were already using estrogen therapy (80), suggesting the existence of a synergism between E2 and T in control of blood pressure. Foam cell formation is an early event in atherosclerosis due to the uptake of LDL by macrophages in the arterial wall (81). Female mice are protected from atherosclerosis compared with males, which is believed to be due to E2 (31). DHT caused a dose-dependent and AR-mediated increase in macrophage cholesterol loading and atherosclerosis-related genes in cultured human male, but not female, macrophages (82, 83). T decreased atherosclerosis in female mice generated on an atherosclerosis-prone apoE-deficient background, but increased atherosclerosis in apoE-deficient male mice (84). In addition, apoE-deficient female mice lacking AR developed diet-induced obesity, dyslipidemia, and atherosclerosis (85). In summary, the physiological importance of T in female metabolic homeostasis is underestimated and may involve beneficial effects on body composition, vascular health, and prevention of atherosclerosis. Figure 3 summarizes T’s actions in female biology.

T promotes metabolic homeostasis in males

In males, T is a hormone that binds the AR and a prohormone that provides a circulating reservoir of E2 and DHT. T deficiency in males leads to sexual dysfunction, depressed mood, anemia, osteoporosis, metabolic syndrome and T2D, and CVD. In the following section, we discuss the effect of T on metabolic homeostasis separated into the effects induced by E2 versus T/DHT.

T-to-E2 conversion maintains bone mass in males.

T’s conversion to E2 by aromatase is instrumental to both normal bone development and preservation of healthy bone metabolism during aging. Support for the importance of E2 in T’s action comes from studies in young males with inactivating mutations of either ERα or aromatase who exhibit abnormal bone growth and development as well as early osteoporosis (86, 87). Furthermore, T treatment of males rendered hypogonadal using gonadotropin-releasing hormone (GnRh) agonists improved bone mineral density, but this effect was abolished with simultaneous administration of an aromatase inhibitor, which blocks T’s conversion to E2 (1). In aging men, E2 is the dominant sex steroid preventing bone resorption, whereas both E2 and T are important in increasing bone formation (88). It is estimated that in males, E2 accounts for approximately 70% of the maintenance of bone mass, with T contributing 30%.

T is an anti-obesity hormone in males.

T deficiency promotes VAT accumulation, and the development of metabolic syndrome in males (reviewed in ref. 89).

T’s aromatization to E2 prevents visceral adiposity in male individuals. Orchiectomized male rodents treated with T or E2 remained lean, while those treated with DHT, which cannot be converted to E2, developed obesity (90). Similarly, in human males rendered hypogonadal using GnRh agonists, T replacement prevented VAT accumulation, an effect that was blocked in the presence of an aromatase inhibitor (1). In addition, human and rodent studies confirmed that inactivating mutations of aromatase increase VAT in males (87, 91). The mechanism by which T’s conversion to E2 prevents VAT in male individuals likely involves an inhibition of adipocytes and adipose progenitors as well as the promotion of lipid oxidation, as described in female individuals.

T has anti-obesity properties mediated via AR actions. In males with genetic androgen resistance (linked to CAG-repeat polymorphisms in the AR gene that decrease AR-mediated gene transcription), a low number of CAG repeats (which increases AR action) was associated with low adiposity and plasma insulin, demonstrating that intact AR action is necessary to prevent VAT accumulation (92). Second, male mice lacking AR developed late-onset visceral obesity and insulin resistance (93, 94). These effects of T on VAT are likely mediated via AR in skeletal muscle, as overexpression of AR selectively in muscle cells of male rats increased muscle mass, which elevated metabolic rate and reduced adipose tissue mass (95). In contrast, male adipocyte-specific AR-deficient mice exhibited no increase in VAT, demonstrating that direct AR action in adipocytes is not necessary for the control of VAT mass (96). In summary, in male individuals, T prevents VAT accumulation via E2’s action on ERα in muscle and adipose (like in females) as well as T/DHT’s action on AR in skeletal muscle.

T prevents T2D in males.

Androgen deprivation therapy (ADT), the standard of treatment of prostate cancer, produces severe T deficiency and is a severe risk factor for developing T2D in males (97, 98). Moderate T deficiency also predisposes to T2D, while T replacement therapy (TRT) prevents or reverses T2D in T-deficient men (99). The antidiabetic effects of T are mediated via a decrease in VAT (described above), an increase in skeletal muscle mass and glycolytic capacity (both of which increase insulin sensitivity), and improved β cell function, as we describe below.

T improves insulin sensitivity via conversion to E2 and DHT, or via the effect of T itself. T promotes insulin sensitivity in skeletal muscle at least partially via an increase in peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC1α), which stimulates mitochondrial biogenesis and skeletal muscle oxidative fibers, and is a molecular marker of muscle insulin sensitivity. A decrease in PGC1α in skeletal muscle was associated with insulin resistance in males (100). Similarly, men with low T exhibited low PGC1α expression in muscle (101). T’s effect on PGC1α is likely to be E2 mediated, as E2 treatment of males increases PGC1α in muscle (102). T’s improvement of insulin sensitivity also requires conversion to DHT. Dual inhibition of the T-to-DHT–converting enzymes 5α-R1 and -R2, but not inhibition of 5α-R2 alone, produced peripheral insulin resistance (103), which is associated with hepatic lipid accumulation in males (104). This suggests that T’s conversion to DHT via 5α-R1 is necessary for insulin sensitivity. T also promotes insulin sensitivity by increasing muscle mass. Surprisingly, the inhibition of T’s conversion to DHT by 5α-R inhibitors had no effect on the ability of T to increase muscle mass and strength (105), indicating that in this context, T directly binds AR and does not require conversion to DHT to promote muscle growth. T also promotes carbohydrate utilization, glycolysis, and glycogen synthesis in skeletal muscle (106, 107), which enhances insulin sensitivity via AR (106). Overexpression of AR in skeletal muscle of male mice produced hypertrophy of glycolytic muscle fibers and increased glucose metabolism (95). Activation of AR also increased glycolysis in male pancreatic islet β cells (108). In contrast, E2 treatment of males (which also decreases T) enhanced lipid oxidation, decreased carbohydrate oxidation during exercise (109) and in cultured male myotubes (110), and increased skeletal muscle expression of medium chain acyl-CoA dehydrogenase, a marker of lipid oxidation (102). Note that individuals assigned male sex at birth who were treated with estrogens (and androgen depletion) as gender-affirming therapy developed insulin resistance (111), suggesting that in males, E2 improves insulin sensitivity in the presence of intact AR action. In summary, in males, T promotes insulin sensitivity with mixed actions of E2 on ERα (insulin sensitivity), DHT on AR (insulin sensitivity), and T on AR (muscle mass).

T’s conversion to DHT enhances insulin secretion in male individuals. Human and rodent male β cells express 5α-R1, which is necessary to convert T to DHT and enhances glucose-stimulated insulin secretion in cultured islets (60). Male mice lacking AR in β cells (βARKO mice) developed β cell failure, leading to inadequate compensation for insulin resistance and hyperglycemia (112). βARKO islets displayed dysregulated genes involved in inflammation and insulin secretion (113). Thus, in the absence of AR in β cells, T cannot maintain normoglycemia, demonstrating the importance of the β cell AR pool to glucose homeostasis in the male. The mechanism involves DHT activation of AR, which amplifies the insulinotropic action of glucagon-like peptide 1 (GLP-1) via its receptor in human β cells, thus enhancing the hypoglycemic and anabolic actions of insulin (108, 112, 114).

T’s conversion to E2 is also important to β cell protection in males. First, male human β cells express aromatase, which is necessary to convert T to E2 and enhances insulin secretion (60). Indeed, in male mice, T’s conversion to E2 via aromatase was necessary to prevent β cell damage from the toxin streptozotocin (115). Second, in multiple male animal models of T2D or β cell failure, E2 protected male islets in vivo from diabetic injuries such as glucolipotoxicity or ER stress (47, 49, 51, 115), suggesting that T’s conversion to E2 is necessary to protect β cell function in males.

Endogenous T promotes cardiovascular health in males.

Endogenous T directly protects the male cardiovascular system. T is a potent vasodilator that acutely increases coronary blood flow (116) and exerts beneficial effects on blood pressure (117). Observational studies demonstrate a direct association between low serum T concentrations and increased risk of CVD in males (118, 119). A meta-analysis of 70 studies concluded that patients with CVD exhibit lower T concentrations (120). Similarly, GnRh agonists, which suppress T production, promote vascular damage (121, 122). Accordingly, a retrospective examination of over 83,000 hypogonadal males showed that normalization of T levels by TRT decreased all-cause mortality, risk of MI, and stroke (123). Moreover, in men with T deficiency and high risk of CVD, the TRAVERSE trial using transdermal T confirmed that TRT does not increase the incidence of major adverse cardiac events (124), providing reassurance about the cardiovascular safety of TRT (125). In summary, despite controversy about T’s effects on CVD, endogenous T prevents CVD and accordingly low T predisposes to CVD. In hypogonadal men, TRT is safe regarding CVD.

Endogenous T promotes cardiovascular health in males via conversion to E2, as demonstrated by the development of endothelial dysfunction and CAD in a young male with absence of functional ERα (126, 127). In middle-aged healthy males, circulating concentrations of E2, not T, are positively associated with FMD (128), while a reduction in plasma E2, through aromatase inhibition, decreases FMD (129). This effect is likely mediated via NO production, as in females. However, the beneficial effect of E2 in males seems to occur within a tight physiological window and in the presence of physiological T concentrations. The early Coronary Drug Project, designed to evaluate the ability of high doses of oral CEE to prevent CAD in males with prior MIs, was discontinued because of increased incidence of MI (130). Similarly, high-dose diethylstilbestrol, a synthetic estrogen, increased the incidence of atherothrombotic disease in males (131), and high-dose ethinyl estradiol, a potent synthetic estrogen used for contraception, increased CVD risk when used as a gender-affirming therapy in transgender individuals assigned male sex at birth (132). However, lower doses of CEE, ethinyl estradiol, or E2 for shorter duration in transgender individuals on gender-affirming therapy improved vascular function (133), enhanced endothelial function and arterial reactivity (134), and promoted endothelium-dependent vasodilation in the microcirculation (135). In older hypogonadal males, E2 enhanced endothelium-mediated vasorelaxation, attenuated vasoconstriction, and reduced blood pressure (136). Estradiol also induced male human coronary relaxation in vitro (137). Studies using genetically modified mice confirmed that the beneficial effects of E2 on vasodilation in male mice, as in female mice, are mediated by ERα (138). Taken together, these data demonstrate that E2 at physiological doses is beneficial for male vascular health.

The T/E2 ratio seems to be a critical parameter for optimal male CVD protection. In the general male population, the T/E2 ratio (both in pg/mL) ranges between 150 and 200 (Figure 2D). In males with existing atherosclerotic disease, a low T/E2 ratio (<120) was associated with increased systemic inflammation and inflammatory plaques, as well as an increased risk of future major adverse cardiovascular events compared with males with a higher T/E2 ratio (>160) (139). In older males, low T and high E2 levels (which decrease the T/E2 ratio) were also associated with an unhealthy artery wall on ultrasound (140, 141). In these studies, the low T/E2 reflected low T with higher E2 concentrations, but still in the physiological range. Thus, it is possible that higher E2 production in the face of low T reflects an endogenous compensatory increase in aromatase activity to lower E2 output in tissue and developing atherosclerosis. The importance of the T/E2 ratio and the stoichiometry of T and E2’s actions may explain why data in male or transgender patients receiving gender-affirming therapy with high-dose estrogens, which suppress T, display increased CVD risk (130–132). However, in transgender individuals receiving gender-affirming therapies, psychosocial stressors may also be implicated in CVD risk (142).

T supplementation decreases HDL in hypogonadal men (143), but produces no change in cholesterol efflux capacity (CEC) of serum HDL, a more reliable CAD risk predictor (144). This decrease in HDL is likely mediated via AR and reproduced by a selective AR modulator (145). In contrast, T is likely to improve atherogenic lipids via conversion to E2, as men with aromatase mutations exhibit low HDL, high LDL, and increased triglycerides, which are corrected by E2 treatment (87, 146). In fact, in males, oral E2 increased HDL (136) and decreased LDL (147), as it does in females. Oral E2 also decreased triglyceride and homocysteine (147). In summary, in males, T promotes vascular protection via conversion to E2, likely by increasing NO and promoting a less atherogenic lipid profile. Consequently, low T, which is associated with low E2, predisposes to CVD. Figure 4 summarizes T’s actions in males.

Conclusions and clinical implications

T and E2 are produced in both sexes at sex-specific concentrations and share similar and potent metabolic functions. The loss of E2 after menopause in females and the decrease in T in aging males both produce metabolic dysfunction and are serious health threats leading to cardiometabolic disease and frailty. The reason that these important metabolic mediators are not prescribed more often relates to myths about the danger of hormones. In particular, there are persistent misconceptions about the risks of estrogen-based therapies in females (148–154). Apart from the purported risk of breast cancer, which has been attributed to synthetic progestins, confusion about the risks of estrogens lies in the too often ignored biological difference between synthetic hormones like CEE, which is associated with CVD, and endogenous and bioidentical E2, which is not associated with negative CVD outcomes. In the case of males and T, myths about risk of prostate cancer and CVD along with its cultural associations with illegally enhancing athletic performance and toxic masculinity has created resistance to consider aging as a treatable condition of T deficiency (155).

It is not known what the role of T in female metabolism is. Is it mediated via T or DHT acting on AR, as animal studies suggest, or is T an additional reservoir for local E2 synthesis in tissues? Clinical trials assessing the effect of T supplementation in postmenopausal women to achieve serum concentrations in the upper limit of female physiology should be considered to ascertain its ability to improve muscle and metabolic function along with its beneficial effects on libido.

Anecdotally, male patients on TRT often enquire about their E2 levels due to fear of “too much female hormone.” Mens’ health clinics even prescribe aromatase inhibitors to suppress E2 production while raising T concentrations. However, we discussed the essential role of T’s conversion to E2 in male bone and vascular health, as well as glucose and lipid homeostasis (not to mention libido and erectile function). Thus, it is our view that E2 should not be suppressed in men, and in fact clinical trials of E2 supplementation should be considered in some men on TRT to decrease LDL cholesterol and improve endothelial function.

Finally, current laboratory measurements of serum T and E2 levels (total or free) poorly reflect tissue and cellular T and E2 concentrations, catabolism, and elimination. Novel assays that provide accurate measures of cellular T and E2 outputs will be informative in clinical studies and are desperately needed.

This work was supported by NIH grants DK074970 (to FMJ), HL133619 (to SHL), P20GM152305 (to FMJ and SHL), and US Department of Veterans Affairs Merit Award BX005812 (to FMJ). Figure 2 was developed from material that is freely available in the CDC’s NHANES databases. Reference to this material does not constitute its endorsement or recommendation by the US government, Department of Health and Human Services or the CDC.

Version 1 09/03/2024

Electronic publication

Figure 1 Origin of T and E2 in males and females.

(A) In males, all T is produced by Leydig cells of the testis. Most E2 (80%) is formed via aromatization of circulating T in the periphery. The testes directly produce approximately 20% of circulating E2. (B) In females of reproductive age, the granulosa cells of the ovaries produce E2, the major circulating estrogen. T is produced by the ovary (25%), the adrenal gland (25%), and in peripheral tissues (50%) following conversion from circulating androstenedione (A4, an androgen that is equally produced by the ovary and the adrenal gland). (C) After menopause, estrone (E1) becomes the major circulating estrogen and is produced by aromatization from A4 (mainly produced by the adrenal gland) in adipose tissue. E1 serves as a reservoir of E2. T is mainly produced by the ovaries (50%) and peripheral conversion of A4 (40%). 17β-HSD, 17β-hydroxysteroid dehydrogenase.

Figure 2 T and E2 concentrations in males and females.

(A) Circulating T and E2 in males and females over the life span. (B) Ratio of T to E2 in males and females. Data in both panels derived from the CDC’s NHANES sex steroids data from 2013–2014 and 2015–2016 databases using sex steroids data from 2013–2014 and 2015–2016 for 7201 males and 7561 females (156, 157). In these data, total hormone (free and protein-bound) was measured using isotope dilution liquid chromatography–tandem mass spectrometry (ID-LC-MS/MS). We binned data from participants ages 6 years and up into decades and plotted as 95% confidence intervals (shown as lighter shading around averaged line). Data outside of the reported range of values were excluded (E2: 2.117 to 1220 pg/mL and T: 4.1 to 15,500 pg/mL).

Figure 3 Cardiometabolic effect of E2 and T in females.

E2’s effects on immune, vascular, lipid, islet, adipose, muscle, and bone biology are represented on the right, while T’s effects on vascular, adipose, muscle, and bone biology are represented on the left.

Figure 4 Cardiometabolic effect of T and E2 in males.

In males, T is converted to E2 and DHT. T’s effects that are mediated via conversion to E2 on immune, vascular, lipid, islet, adipose, muscle, and bone biology as well as sexual function are represented on the right, while T’s effects mediated via direct action or conversion to DHT on vascular, lipid, islet adipose, muscle, and bone biology are represented on the left. DHT, dihydrotestosterone.

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2024, Mauvais-Jarvis et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2024;134(17):e180073. https://doi.org/10.1172/JCI180073.
==== Refs
1 Finkelstein JS et al Gonadal steroids and body composition, strength, and sexual function in men N Engl J Med 2013 369 11 1011 1022 10.1056/NEJMoa1206168 24024838
2 Davis SR et al Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial Menopause 2006 13 3 387 396 10.1097/01.gme.0000179049.08371.c7 16735935
3 Vermeulen A et al Estradiol in elderly men Aging Male 2002 5 2 98 102 10.1080/tam.5.2.98.102 12198740
4 Vermeulen A Verdonck L Factors affecting sex hormone levels in postmenopausal women J Steroid Biochem 1979 11 1c 899 904 10.1016/0022-4731(79)90027-X 491650
5 Forney JP et al Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia J Clin Endocrinol Metab 1981 53 1 192 199 10.1210/jcem-53-1-192 7240376
6 Burger HG Androgen production in women Fertil Steril 2002 77 Suppl 4 S3 S5 10.1016/S0015-0282(02)03008-X 12007895
7 Longcope C Adrenal and gonadal androgen secretion in normal females Clin Endocrinol Metab 1986 15 2 213 228 10.1016/S0300-595X(86)80021-4 3013468
8 Judd HL Fournet N Changes of ovarian hormonal function with aging Exp Gerontol 1994 29 3–4 285 298 10.1016/0531-5565(94)90008-6 7925749
9 Adashi EY The climacteric ovary as a functional gonadotropin-driven androgen-producing gland Fertil Steril 1994 62 1 20 27 10.1016/S0015-0282(16)56810-1 8005293
10 Manson JE et al Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials JAMA 2013 310 13 1353 1368 10.1001/jama.2013.278040 24084921
11 Lufkin EG et al Treatment of postmenopausal osteoporosis with transdermal estrogen Ann Intern Med 1992 117 1 1 9 10.7326/0003-4819-117-1-1 1534476
12 Rocca WA et al Bilateral oophorectomy and accelerated aging: cause or effect? J Gerontol A Biol Sci Med Sci 2017 72 9 1213 1217 10.1093/gerona/glx026 28329133
13 Mytton J et al Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage BMJ 2017 356 j372 10.1136/bmj.j372 28167486
14 Roeters van Lennep JE et al Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis Eur J Prev Cardiol 2016 23 2 178 186 10.1177/2047487314556004 25331207
15 Muka T et al Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis JAMA Cardiol 2016 1 7 767 776 10.1001/jamacardio.2016.2415 27627190
16 Green DJ et al Is flow-mediated dilation nitric oxide mediated?: A meta-analysis Hypertension 2014 63 2 376 382 10.1161/HYPERTENSIONAHA.113.02044 24277765
17 Matsuzawa Y et al Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis J Am Heart Assoc 2015 4 11 e002270 10.1161/JAHA.115.002270 26567372
18 Hopkins ND et al Age and sex relationship with flow-mediated dilation in healthy children and adolescents J Appl Physiol (1985) 2015 119 8 926 933 10.1152/japplphysiol.01113.2014 26251515
19 Skaug EA et al Age and gender differences of endothelial function in 4739 healthy adults: the HUNT3 Fitness Study Eur J Prev Cardiol 2013 20 4 531 540 10.1177/2047487312444234 22456692
20 Moreau KL et al Endothelial function is impaired across the stages of the menopause transition in healthy women J Clin Endocrinol Metab 2012 97 12 4692 4700 10.1210/jc.2012-2244 22969140
21 Samargandy S et al Trajectories of blood pressure in midlife women: does menopause matter? Circ Res 2022 130 3 312 322 10.1161/CIRCRESAHA.121.319424 35113663
22 Chappell MC et al Estrogen and salt sensitivity in the female mRen(2). Lewis rat Am J Physiol Regul Integr Comp Physiol 2006 291 5 R1557 R1563 10.1152/ajpregu.00051.2006 16825422
23 Madika AL et al Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the E3N cohort Menopause 2021 28 11 1204 1208 10.1097/GME.0000000000001839 34581294
24 Kalenga CZ et al Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women: a prospective population-based study Hypertension 2023 80 7 1463 1473 10.1161/HYPERTENSIONAHA.122.19938 37272379
25 Blacher J et al Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients Hypertension 1999 33 5 1111 1117 10.1161/01.HYP.33.5.1111 10334796
26 Laogun AA Gosling RG In vivo arterial compliance in man Clin Phys Physiol Meas 1982 3 3 201 212 10.1088/0143-0815/3/3/004 7140158
27 Khan ZA et al Serial studies in subclinical atherosclerosis during menopausal transition (from the Study of Women’s Health Across the Nation) Am J Cardiol 2018 122 7 1161 1168 10.1016/j.amjcard.2018.06.039 30077316
28 Waddell TK et al Women exhibit a greater age-related increase in proximal aortic stiffness than men J Hypertens 2001 19 12 2205 2212 10.1097/00004872-200112000-00014 11725165
29 Klein SL Flanagan KL Sex differences in immune responses Nat Rev Immunol 2016 16 10 626 638 10.1038/nri.2016.90 27546235
30 Mauvais-Jarvis F et al Estradiol, progesterone, immunomodulation, and COVID-19 outcomes Endocrinology 2020 161 9 bqaa127 10.1210/endocr/bqaa127 32730568
31 Cann JA et al Timing of estrogen replacement influences atherosclerosis progression and plaque leukocyte populations in ApoE-/- mice Atherosclerosis 2008 201 1 43 52 10.1016/j.atherosclerosis.2008.01.018 18374339
32 Clarkson TB et al Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future Menopause 2013 20 3 342 353 10.1097/gme.0b013e3182843aad 23435033
33 Boardman HM et al Hormone therapy for preventing cardiovascular disease in post-menopausal women Cochrane Database Syst Rev 2015 2015 3 CD002229 25754617
34 SenthilKumar G et al Estrogen and the vascular endothelium: the unanswered questions Endocrinology 2023 164 6 bqad079 10.1210/endocr/bqad079 37207450
35 Rossouw JE et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial JAMA 2002 288 3 321 333 10.1001/jama.288.3.321 12117397
36 Bhavnani BR Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer’s J Steroid Biochem Mol Biol 2003 85 2-5 473 482 10.1016/S0960-0760(03)00220-6 12943738
37 Novensa L et al Equine estrogens impair nitric oxide production and endothelial nitric oxide synthase transcription in human endothelial cells compared with the natural 17{beta}-estradiol Hypertension 2010 56 3 405 411 10.1161/HYPERTENSIONAHA.110.151969 20606108
38 Mauvais-Jarvis F Sex differences in energy metabolism: natural selection, mechanisms and consequences Nat Rev Nephrol 2024 20 1 56 69 10.1038/s41581-023-00781-2 37923858
39 Klaver M et al Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study Eur J Endocrinol 2018 178 2 163 171 10.1530/EJE-17-0496 29183889
40 Salpeter SR et al Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women Diabetes Obes Metab 2006 8 5 538 554 10.1111/j.1463-1326.2005.00545.x 16918589
41 Marlatt KL et al Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women Eur J Endocrinol 2020 183 4 439 452 10.1530/EJE-20-0619 32698159
42 Mauvais-Jarvis F et al Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications Endocr Rev 2017 38 3 173 188 10.1210/er.2016-1146 28323934
43 Speksnijder EM et al Effect of postmenopausal hormone therapy on glucose regulation in women with type 1 or type 2 diabetes: a systematic review and meta-analysis Diabetes Care 2023 46 10 1866 1875 10.2337/dc23-0451 37729504
44 de Lauzon-Guillain B et al Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l’Education Nationale (E3N) cohort Diabetologia 2009 52 10 2092 2100 10.1007/s00125-009-1456-y 19629429
45 Mauvais-Jarvis F et al The role of estrogens in control of energy balance and glucose homeostasis Endocr Rev 2013 34 3 309 338 10.1210/er.2012-1055 23460719
46 Ribas V et al Skeletal muscle action of estrogen receptor α is critical for the maintenance of mitochondrial function and metabolic homeostasis in females Sci Transl Med 2016 8 334 334ra54 10.1126/scitranslmed.aad3815 27075628
47 Tiano JP Mauvais-Jarvis F Importance of oestrogen receptors to preserve functional β-cell mass in diabetes Nat Rev Endocrinol 2012 8 6 342 351 10.1038/nrendo.2011.242 22330739
48 Lovre D et al Conjugated estrogens and bazedoxifene improve β cell function in obese menopausal women J Endocr Soc 2019 3 8 1583 1594 10.1210/js.2019-00074 31384719
49 Tiano JP et al Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents β cell failure in rodent models of type 2 diabetes J Clin Invest 2011 121 8 3331 3342 10.1172/JCI44564 21747171
50 Wong WP et al Extranuclear estrogen receptor-{alpha} stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis Proc Natl Acad Sci U S A 2010 107 29 13057 13062 10.1073/pnas.0914501107 20616010
51 Xu B et al Estrogens promote misfolded proinsulin degradation to protect insulin production and delay diabetes Cell Rep 2018 24 1 181 196 10.1016/j.celrep.2018.06.019 29972779
52 El Khoudary SR et al Low-density lipoprotein subclasses over the menopausal transition and risk of coronary calcification and carotid atherosclerosis: the SWAN Heart and HDL ancillary studies Menopause 2023 30 10 1006 1013 10.1097/GME.0000000000002245 37738035
53 Kobayashi A et al Mechanisms underlying the regulation of mitochondrial respiratory chain complexes by nuclear steroid receptors Int J Mol Sci 2020 21 18 6683 10.3390/ijms21186683 32932692
54 Klinge CM Estrogenic control of mitochondrial function Redox Biol 2020 31 101435 10.1016/j.redox.2020.101435 32001259
55 Beikoghli Kalkhoran S Kararigas G Oestrogenic regulation of mitochondrial dynamics Int J Mol Sci 2022 23 3 1118 10.3390/ijms23031118 35163044
56 Ventura-Clapier R et al Mitochondria: a central target for sex differences in pathologies Clin Sci (Lond) 2017 131 9 803 822 10.1042/CS20160485 28424375
57 Ehrmann DA et al Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome J Clin Endocrinol Metab 2006 91 1 48 53 10.1210/jc.2005-1329 16249284
58 Uhlen M et al Proteomics. Tissue-based map of the human proteome Science 2015 347 6220 1260419 10.1126/science.1260419 25613900
59 Nash C et al Genome-wide analysis of androgen receptor binding and transcriptomic analysis in mesenchymal subsets during prostate development Dis Model Mech 2019 12 7 dmm039297 10.1242/dmm.039297 31350272
60 Xu W et al Intracrine testosterone activation in human pancreatic β-cells stimulates insulin secretion Diabetes 2020 69 11 2392 2399 10.2337/db20-0228 32855171
61 Miller KK et al Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study J Clin Endocrinol Metab 2006 91 5 1683 1690 10.1210/jc.2005-2596 16478814
62 Iellamo F et al Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study J Am Coll Cardiol 2010 56 16 1310 1316 10.1016/j.jacc.2010.03.090 20888520
63 Zang H et al Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women Fertil Steril 2006 86 1 136 144 10.1016/j.fertnstert.2005.12.039 16750207
64 Huang G et al Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial Menopause 2014 21 6 612 623 10.1097/GME.0000000000000093 24281237
65 Tapper J et al The effects of testosterone administration on muscle areas of the trunk and pelvic floor in hysterectomized women with low testosterone levels: proof-of-concept study Menopause 2019 26 12 1405 1414 10.1097/GME.0000000000001410 31479032
66 Davis SR et al Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality Maturitas 1995 21 3 227 236 10.1016/0378-5122(94)00898-H 7616872
67 Miller BE et al Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density Menopause 2000 7 5 318 326 10.1097/00042192-200007050-00006 10993031
68 Miller KK et al Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism J Clin Endocrinol Metab 2007 92 7 2474 2479 10.1210/jc.2007-0195 17426086
69 Kocoska-Maras L et al Testosterone addition to estrogen therapy - effects on inflammatory markers for cardiovascular disease Gynecol Endocrinol 2009 25 12 823 827 10.3109/09513590903056134 19906002
70 Chiuve SE et al Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women J Clin Endocrinol Metab 2004 89 5 2207 2213 10.1210/jc.2003-031564 15126543
71 Määttä JA et al Inactivation of the androgen receptor in bone-forming cells leads to trabecular bone loss in adult female mice Bonekey Rep 2013 2 440 10.1038/bonekey.2013.174 24422138
72 Hirschberg AL Hyperandrogenism and cardiometabolic risk in pre- and postmenopausal women-what is the evidence? J Clin Endocrinol Metab 2023 109 5 1202 1213 10.1210/clinem/dgad590 37886900
73 Hak AE et al High-dose testosterone is associated with atherosclerosis in postmenopausal women Maturitas 2007 56 2 153 160 10.1016/j.maturitas.2006.07.004 16938416
74 Sievers C et al Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients Eur J Endocrinol 2010 163 4 699 708 10.1530/EJE-10-0307 20685832
75 Bernini GP et al Endogenous androgens and carotid intimal-medial thickness in women J Clin Endocrinol Metab 1999 84 6 2008 2012 10.1210/jcem.84.6.5824 10372702
76 Golden SH et al Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort Am J Epidemiol 2002 155 5 437 445 10.1093/aje/155.5.437 11867355
77 Montalcini T et al Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women Nutr Metab Cardiovasc Dis 2007 17 10 705 711 10.1016/j.numecd.2006.09.007 17395446
78 Kaczmarek A et al The association of lower testosterone level with coronary artery disease in postmenopausal women Int J Cardiol 2003 87 1 53 57 10.1016/S0167-5273(02)00203-6 12468054
79 Mendivil CO et al Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease Circulation 2011 124 19 2065 2072 10.1161/CIRCULATIONAHA.111.056986 21986282
80 Worboys S et al Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen J Clin Endocrinol Metab 2001 86 1 158 161 10.1210/jcem.86.1.7103 11231994
81 Ross R The pathogenesis of atherosclerosis: a perspective for the 1990s Nature 1993 362 6423 801 809 10.1038/362801a0 8479518
82 McCrohon JA et al Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis Circulation 2000 101 3 224 226 10.1161/01.CIR.101.3.224 10645914
83 Ng MK et al Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis J Am Coll Cardiol 2003 42 7 1306 1313 10.1016/j.jacc.2003.07.002 14522500
84 von Dehn G et al Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones Horm Metab Res 2001 33 2 110 114 10.1055/s-2001-12405 11294492
85 Fagman JB et al The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice FASEB J 2015 29 4 1540 1550 10.1096/fj.14-259234 25550469
86 Smith EP et al Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man N Engl J Med 1994 331 16 1056 1061 10.1056/NEJM199410203311604 8090165
87 Carani C et al Effect of testosterone and estradiol in a man with aromatase deficiency N Engl J Med 1997 337 2 91 95 10.1056/NEJM199707103370204 9211678
88 Falahati-Nini A et al Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men J Clin Invest 2000 106 12 1553 1560 10.1172/JCI10942 11120762
89 Navarro G et al The role of androgens in metabolism, obesity, and diabetes in males and females Obesity (Silver Spring) 2015 23 4 713 719 10.1002/oby.21033 25755205
90 Moverare-Skrtic S et al Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice Obesity (Silver Spring) 2006 14 4 662 672 10.1038/oby.2006.75 16741268
91 Jones ME et al Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity Proc Natl Acad Sci U S A 2000 97 23 12735 12740 10.1073/pnas.97.23.12735 11070087
92 Zitzmann M et al The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men Diabetologia 2003 46 1 31 39 10.1007/s00125-002-0980-9 12637980
93 Fan W et al Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion Diabetes 2005 54 4 1000 1008 10.2337/diabetes.54.4.1000 15793238
94 Lin HY et al Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor Diabetes 2005 54 6 1717 1725 10.2337/diabetes.54.6.1717 15919793
95 Fernando SM et al Myocyte androgen receptors increase metabolic rate and improve body composition by reducing fat mass Endocrinology 2010 151 7 3125 3132 10.1210/en.2010-0018 20427479
96 Yu IC et al Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue Endocrinology 2008 149 5 2361 2368 10.1210/en.2007-0516 18276764
97 Keating NL et al Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 2006 24 27 4448 4456 10.1200/JCO.2006.06.2497 16983113
98 Keating NL et al Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 2010 102 1 39 46 10.1093/jnci/djp404 19996060
99 Wittert G et al Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial Lancet Diabetes Endocrinol 2021 9 1 32 45 10.1016/S2213-8587(20)30367-3 33338415
100 Mootha VK et al PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes Nat Genet 2003 34 3 267 273 10.1038/ng1180 12808457
101 Pitteloud N et al Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men Diabetes Care 2005 28 7 1636 1642 10.2337/diacare.28.7.1636 15983313
102 Maher AC et al Men supplemented with 17beta-estradiol have increased beta-oxidation capacity in skeletal muscle Physiol Genomics 2010 42 3 342 347 10.1152/physiolgenomics.00016.2010 20484157
103 Upreti R et al 5α-reductase type 1 modulates insulin sensitivity in men J Clin Endocrinol Metab 2014 99 8 E1397 E1406 10.1210/jc.2014-1395 24823464
104 Hazlehurst JM et al Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man J Clin Endocrinol Metab 2016 101 1 103 113 10.1210/jc.2015-2928 26574953
105 Bhasin S et al Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial JAMA 2012 307 9 931 939 10.1001/jama.2012.227 22396515
106 Ghaibour K et al Androgen receptor coordinates muscle metabolic and contractile functions J Cachexia Sarcopenia Muscle 2023 14 4 1707 1720 10.1002/jcsm.13251 37208984
107 Haren MT et al Testosterone modulates gene expression pathways regulating nutrient accumulation, glucose metabolism and protein turnover in mouse skeletal muscle Int J Androl 2011 34 1 55 68 10.1111/j.1365-2605.2010.01061.x 20403060
108 Xu W et al Architecture of androgen receptor pathways amplifying glucagon-like peptide-1 insulinotropic action in male pancreatic β cells Cell Rep 2023 42 5 112529 10.1016/j.celrep.2023.112529 37200193
109 Hamadeh MJ et al Estrogen supplementation reduces whole body leucine and carbohydrate oxidation and increases lipid oxidation in men during endurance exercise J Clin Endocrinol Metab 2005 90 6 3592 3599 10.1210/jc.2004-1743 15755861
110 Salehzadeh F et al Testosterone or 17{beta}-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes J Endocrinol 2011 210 2 219 229 10.1530/JOE-10-0497 21632903
111 Deischinger C et al Effects of gender-affirming hormone therapy on cardiovascular risk factors focusing on glucose metabolism in an Austrian transgender cohort Int J Transgend Health 2023 24 4 499 509 10.1080/26895269.2022.2123425 37901063
112 Navarro G et al Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male Cell Metab 2016 23 5 837 851 10.1016/j.cmet.2016.03.015 27133133
113 Xu W et al Intracrine testosterone activation in human pancreatic β cells stimulates insulin secretion Diabetes 2020 69 11 2392 2399 10.2337/db20-0228 32855171
114 Xu W, et al. Emerging role of testosterone in pancreatic β-cell function and insulin secretion [posted on January 1, 2019]. J Endocrinol. 10.1530/joe-18-0573
115 Le May C et al Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice Proc Natl Acad Sci U S A 2006 103 24 9232 9237 10.1073/pnas.0602956103 16754860
116 Webb CM et al Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease Circulation 1999 100 16 1690 1696 10.1161/01.CIR.100.16.1690 10525487
117 Zitzmann M Nieschlag E Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men J Clin Endocrinol Metab 2007 92 10 3844 3853 10.1210/jc.2007-0620 17635942
118 Yeap BB et al Lower testosterone levels predict incident stroke and transient ischemic attack in older men J Clin Endocrinol Metab 2009 94 7 2353 2359 10.1210/jc.2008-2416 19351733
119 Soisson V et al A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study Maturitas 2013 75 3 282 288 10.1016/j.maturitas.2013.04.012 23706278
120 Araujo AB et al Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis J Clin Endocrinol Metab 2011 96 10 3007 3019 10.1210/jc.2011-1137 21816776
121 Dockery F et al Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia Clin Sci (Lond) 2003 104 2 195 201 10.1042/cs1040195 12546642
122 Smith JC et al The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer J Clin Endocrinol Metab 2001 86 9 4261 4267 10.1210/jcem.86.9.7851 11549659
123 Sharma R et al Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men Eur Heart J 2015 36 40 2706 2715 10.1093/eurheartj/ehv346 26248567
124 Lincoff AM et al Cardiovascular safety of testosterone-replacement therapy N Engl J Med 2023 389 2 107 117 10.1056/NEJMoa2215025 37326322
125 Lim GB Testosterone-replacement therapy does not increase cardiac events in men with hypogonadism Nat Rev Cardiol 2023 20 9 581 10.1038/s41569-023-00909-8 37391471
126 Sudhir K et al Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene Lancet 1997 349 9059 1146 1147 10.1016/S0140-6736(05)63022-X 9113019
127 Sudhir K et al Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man Circulation 1997 96 10 3774 3777 10.1161/01.CIR.96.10.3774 9396482
128 Saltiki K et al Endogenous estrogen levels are associated with endothelial function in males independently of lipid levels Endocrine 2010 37 2 329 335 10.1007/s12020-010-9307-7 20960271
129 Lew R et al Endogenous estrogens influence endothelial function in young men Circ Res 2003 93 11 1127 1133 10.1161/01.RES.0000103633.57225.BC 14592997
130 The Coronary Drug Project The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group JAMA 1973 226 6 652 657 10.1001/jama.1973.03230060030009 4356847
131 Byar DP Corle DK Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies NCI Monogr 1988 7 165 170 3050535
132 Gooren LJ et al Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern Eur J Endocrinol 2014 170 6 809 819 10.1530/EJE-14-0011 24616414
133 New G et al Long-term estrogen therapy improves vascular function in male to female transsexuals J Am Coll Cardiol 1997 29 7 1437 1444 10.1016/S0735-1097(97)00080-6 9180101
134 McCrohon JA et al Arterial reactivity is enhanced in genetic males taking high dose estrogens J Am Coll Cardiol 1997 29 7 1432 1436 10.1016/S0735-1097(97)00063-6 9180100
135 New G et al Long-term oestrogen therapy is associated with improved endothelium-dependent vasodilation in the forearm resistance circulation of biological males Clin Exp Pharmacol Physiol 2000 27 1-2 25 33 10.1046/j.1440-1681.2000.03195.x 10696525
136 Komesaroff PA et al Low-dose estrogen supplementation improves vascular function in hypogonadal men Hypertension 2001 38 5 1011 1016 10.1161/hy1101.095006 11711490
137 Chester AH et al Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms Coron Artery Dis 1995 6 5 417 422 10.1097/00019501-199505000-00009 7655729
138 Rubanyi GM et al Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption J Clin Invest 1997 99 10 2429 2437 10.1172/JCI119426 9153286
139 van Koeverden ID et al Testosterone to oestradiol ratio reflects systemic and plaque inflammation and predicts future cardiovascular events in men with severe atherosclerosis Cardiovasc Res 2019 115 2 453 462 10.1093/cvr/cvy188 30052805
140 Naessen T et al Higher endogenous estrogen levels in 70-year-old women and men: an endogenous response to counteract developing atherosclerosis? Menopause 2012 19 12 1322 1328 10.1097/gme.0b013e31825ea8c1 22990754
141 Naessen T et al Endogenous steroids measured by high-specificity liquid chromatography-tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old men and women J Clin Endocrinol Metab 2010 95 4 1889 1897 10.1210/jc.2009-1722 20164295
142 Streed CG Jr et al Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the American Heart Association Circulation 2021 144 6 e136 10.1161/CIR.0000000000001003 34235936
143 Whitsel EA et al Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis Am J Med 2001 111 4 261 269 10.1016/S0002-9343(01)00833-6 11566455
144 Rohatgi A et al HDL cholesterol efflux capacity and incident cardiovascular events N Engl J Med 2014 371 25 2383 2393 10.1056/NEJMoa1409065 25404125
145 Guo W et al Effect of selective androgen receptor modulator on cholesterol efflux capacity, size, and subspecies of HDL particles J Endocr Soc 2022 6 8 bvac099 10.1210/jendso/bvac099 35822201
146 Bilezikian JP et al Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency N Engl J Med 1998 339 9 599 603 10.1056/NEJM199808273390905 9718379
147 Giri S et al Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men Atherosclerosis 1998 137 2 359 366 10.1016/S0021-9150(98)00022-7 9622279
148 Huang AJ Grady D Menopausal hormone therapy for prevention of chronic conditions: when is enough, enough? JAMA 2022 328 17 1712 1713 10.1001/jama.2022.19098 36318153
149 Pickar JH Independent conclusions? Climacteric 2023 26 2 73 74 10.1080/13697137.2022.2159168 36943104
150 Glynne S et al Hormone therapy for the prevention of chronic conditions in postmenopausal persons JAMA 2023 329 11 940 941 10.1001/jama.2023.0180 36943221
151 Chlebowski RT Aragaki AK Hormone therapy for the prevention of chronic conditions in postmenopausal persons JAMA 2023 329 11 942 10.1001/jama.2023.0186 36943219
152 Nachtigall M et al Hormone therapy for the prevention of chronic conditions in postmenopausal persons JAMA 2023 329 11 940 10.1001/jama.2023.0183 36943220
153 Gartlehner G Kahwati L Hormone therapy for the prevention of chronic conditions in postmenopausal persons-reply JAMA 2023 329 11 943 10.1001/jama.2023.0192 36943216
154 Anderson GL Hormone therapy for the prevention of chronic conditions in postmenopausal persons JAMA 2023 329 11 941 10.1001/jama.2023.0189 36943218
155 Morgentaler A et al Recognizing the true value of testosterone therapy in health care Androg Clin Res Ther 2022 3 1 217 223 36643964
156 Centers for Disease Control and Prevention. Laboratory Data - Continuous NHANES. https://wwwn.cdc.gov/Nchs/Nhanes/Search/DataPage.aspx?Component=Laboratory&Cycle=2013-4 Updated June 2024. Accessed July 16, 2024
157 Centers for Disease Control and Prevention (CDC), and National Center for Health Statistics (NCHS). Hyattsville, MD: U.S. Department of Health and Human Services; 2015-16:https://wwwn.cdc.gov/Nchs/Nhanes/Search/DataPage.aspx?Component=Laboratory&Cycle=2015-6
